SUBCONJUNCTIVAL DEPOT FORMING FORMULATIONS FOR OCULAR DRUG DELIVERY

According to the present disclosure, the use of a liposomal formulation comprising one or more phospholipids in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is provided. Preferred phospholipids include POPC and DOTAP, POPC and POPG, DPTAP and POPG, DMTAP and POPG, DPPC and DPTAP, DPPC and DPPG, DMPC and DMTAP, or DMPC and DMPG. In a separate embodiment, the use of a particulate formulation comprising a plurality of poly(lactic-co-glycolic acid) particles in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is also provided. In either embodiments, the posterior ocular segment diseases comprise age related degeneration, diabetic macular edema or retinopathy and anterior ocular segment diseases comprise glaucoma, cataract or uveitis. 122-. (canceled)23. A method of treating posterior and/or anterior ocular segment diseases by administering a liposomal formulation comprising one or more phospholipids , wherein the one or more phospholipids form at least one liposome each comprising at least one phospholipid bilayer , and wherein the one or more phospholipids comprise 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) , 1 ,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC) , 1 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) , 1 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) , 1 ,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP) , 1 ,2-dimyristoyl-3-trimethylammonium-propane (DMTAP) , 1 ,2-dioleoyl-3-trimethylammonium-propane (DOTAP) , 1 ,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG) , 1 ,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DMPG) , 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) , hydrogenated soybean phosphatidylcholine (HSPC) , 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) , or their combination thereof.24. The method according to claim 23 , wherein the combination ...

COMPOSITE MATERIAL WITH ENHANCED MECHANICAL PROPERTIES AND A METHOD TO FABRICATE THE SAME

According to the present disclosure, a hydrophobic polymeric composite comprising a hydrophobic polymer matrix with hydrophobically modified particles dispersed therein is provided. The hydrophobically modified particles may be derived from hydrophilic particles modified with organic moieties. The hydrophobically modified particles may also take in the form of core-shell fibers with hydrophilic particles encapsulated inside the core of said fibers or in the form of monolithic fibers embedded with hydrophilic particles. The method for making hydrophobic polymeric composite comprising each of the various hydrophobically modified particles is also provided. The hydrophobic polymer matrix can be chosen from poly(alpha-hydroxyesters), of carbonates, polyurethanes or polyalkanoates. For example, hydrophilic particles, such as barium sulphate, zirconium oxide, tantalum oxide or bismuth oxide, are dispersed in the hydrophobic biodegradable polymers, such as poly-(L-lactide) (PLLA). 1. A hydrophobic polymeric composite comprising a hydrophobic polymer matrix with hydrophobically modified particles dispersed therein , wherein the hydrophobically modified particles each comprises a hydrophilic particle comprising an organic moiety which changes the hydrophilic particle into a hydrophobically modified particle , and wherein the hydrophilic particle comprises barium sulphate , zirconia , tantalum oxide , or bismuth oxide.2. The hydrophobic polymeric composite according to claim 1 , wherein the hydrophobic polymer matrix comprises poly(alpha-hydroxyesters) claim 1 , polycarbonates claim 1 , polyurethanes claim 1 , or polyalkanoates.3. The hydrophobic polymeric composite according to claim 2 , wherein the poly(alpha-hydroxyesters) are selected from the group consisting of polylactic acid claim 2 , poly-(l-lactide) claim 2 , poly-(d claim 2 ,l-lactide) claim 2 , poly(glycolic) acid claim 2 , poly(lactide-co-glycoside acid) claim 2 , polycaprolactone claim 2 , poly(p-dioxanone) ...

DELIVERY OF NITRIC OXIDE-RELEASING PHOSPHOLIPIDS, LIPOSOMES, AND HIGH DENSITY LIPOPROTEIN-LIKE NANOPARTICLES (HDL NPS) BY DRUG ELUTING STENTS AND INTRA-ARTERIAL INJECTION

Nanostructures having a lipid layer which are useful for delivering nitric oxide are provided herein. Methods of treating disease using the nanostructures are also provided, including methods of treating vascular diseases, angiogenesis, ischemia- reperfusion, etc. Implantable devices coated with the nanostructures are also encompassed within the invention. 1. An implantable device comprising a nanostructure of reservoir molecules that are reservoirs for nitric oxide.2. The implantable device of claim 1 , wherein the reservoir molecule is a lipid.3. The implantable device of claim 2 , wherein the lipid is a modified phospholipid.4. The implantable device of claim 1 , further comprising an apolipoprotein.5. (canceled)6. (canceled)7. The implantable device of claim 1 , wherein the nanostructure has a core and a lipid bilayer or monolayer.8. The implantable device of claim 8 , wherein the core is a gold core.9. (canceled)10. The implantable device of claim 1 , wherein the reservoir molecule is not a lipid.11. The implantable device of claim 1 , wherein the reservoir molecules contain an NO donating group.12. The implantable device of claim 1 , wherein the implantable device is a stent.13. (canceled)14. A method for delivering NO to a subject comprising:administering to a subject having a NO mediated disorder by injection, through a catheter or on an implantable device, a nanostructure of reservoir molecules and nitric oxide.15. The method of claim 14 , wherein the NO mediated disorder is angiogenesis ischemia-reperfusion claim 14 , restenosis claim 14 , atherosclerosis claim 14 , dysregulated blood pressure claim 14 , or graft rejection after transplantation.1620-. (canceled)21. The method of claim 1 , wherein the reservoir molecule is a lipid.22. The method of claim 21 , wherein the lipid is a modified phospholipid.23. The method of claim 14 , wherein the nanostructure further comprises an apolipoprotein.24. (canceled)25. (canceled)26. The method of claim 14 , wherein ...

SCAFFOLD FOR VASCULAR PROTHESIS AND A METHOD OF FABRICATING THEREOF

A scaffold for vascular prosthesis of blood vessel may include an inner tube made of elastomeric material, and an outer mesh which surrounds the inner tube and which is made of a material of a higher stiffness than the elastomeric material of the inner tube. The outer mesh may include a plurality of coils wound around the inner tube. Each of said coils may be parallel to each other. The outer mesh may further include at least one linking strand connecting two or more said coils to each other. Each of said coils may include one or more axially-oriented-kinks. 1. A scaffold for vascular prosthesis of blood vessel comprising:an inner tube made of elastomeric material; andan outer mesh which surrounds the inner tube and which is made of a material of a higher stiffness than the elastomeric material of the inner tube, a plurality of coils wound around the inner tube, each of said coils being parallel to each other, and', 'at least one linking strand connecting two or more said coils to each other,, 'wherein the outer mesh comprises'}wherein each of said coils comprises one or more axially-oriented-kinks.2. The scaffold as claimed in claim 1 , wherein the elastomeric material of the inner tube comprises elastomeric copolymer claim 1 , and wherein the elastomeric copolymer comprises poly-L-lactide-co-caprolactone (PLC) claim 1 , or bio-elastomeric poly-caprolactone-glycolide (PCG) claim 1 , or poly-caprolactone (PCL) claim 1 , or poly-L-lactide (PLLA) claim 1 , or poly-lactide (PLA) claim 1 , or polyurethane (PU) claim 1 , or thermoplastic polyurethane (TPU).3. The scaffold as claimed in claim 2 , wherein the PLC is with a lactide to caprolactone ratio ranging from 50:50 to 95:50.4. The scaffold as claimed in claim 2 , wherein the PCG is with a caprolactone to glycolide ratio ranging from 35:65 to 50:50.5. The scaffold as claimed in claim 1 , wherein the at least one axially-oriented-kink has a profile comprising any one of a single bend profile claim 1 , a double bend ...

POLYMERIC STENT AND METHOD OF MANUFACTURE

A stent formed of polymeric material, useful for the expansion of a lumen and the delivery of one or more therapeutic agents in situ is disclosed. The stent may be multi-layered, and may change shape at a state transition temperature governed by the materials forming the layers. Methods of use and manufacture are also disclosed.

EMBOLIC DEVICE, AN APPARATUS FOR EMBOLIZING A TARGET VASCULAR SITE AND A METHOD THEREOF

According to embodiments of the present invention, an embolic device for embolizing a target vascular site is provided. The embolic device includes a biodegradable shape memory element having an original shape and a deformed shape, wherein the biodegradable shape memory element in the deformed shape is in at least one dimension of a smaller size than the biodegradable shape memory element in the original shape, and wherein the biodegradable shape memory element is provided in the deformed shape and configured to resume the original shape in response to an external stimulus being applied to the biodegradable shape memory element in its deformed shape, to embolize the target vascular site and prevent fluid flow through the target vascular site. According to further embodiments of the present invention, an apparatus for embolizing a target vascular site and a method thereof are also provided. 1. An embolic device for embolizing a target vascular site , the embolic device comprising: wherein the biodegradable shape memory element in the deformed shape is in at least one dimension of a smaller size than the biodegradable shape memory element in the original shape; and', 'wherein the biodegradable shape memory element is provided in the deformed shape and configured to resume the original shape in response to an external stimulus being applied to the biodegradable shape memory element in its deformed shape, to embolize the target vascular site and prevent fluid flow through the target vascular site., 'a biodegradable shape memory element having an original shape and a deformed shape,'}2. The embolic device of claim 1 , wherein the biodegradable shape memory element is configured to transit from the original shape to the deformed shape in response to an external stimulus being applied- to the biodegradable shape memory element in its original shape.3. The embolic device of claim 1 , wherein the biodegradable shape memory element comprises a biodegradable shape memory ...

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. 1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmor contains sufentanil and has an area of 0.5 to 40 cm.3. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmand contains no permeation enhancer.4. The patch of wherein said patch exhibits a normalized Cof 3.3 to 82.5 ng/(ml(mg/h)).5. The patch of wherein the patch exhibits a steady state drug flux of 0.1 to 20 μg/(cmhr).6. The patch of wherein said patch exhibits a standardized Cof 0.001 to 0.2 ng/(ml-cm).7. The patch of wherein the reservoir contains sufentanil and has an area of 0.5 to 40 cm.8. The patch of wherein said reservoir comprises an amount of dissolved fentanyl analog sufficient to induce and maintain analgesia for 3-7 days.9. The patch of wherein said fentanyl analog is selected from the group consisting of alfentanil claim 8 , lofentanil claim 8 , remifentanil and sufentanil.10. The patch of wherein said reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of 1 wt % to 25 wt % claim 8 ,11. The patch of wherein the reservoir comprises 0.05 to 1.75 mg/cmof fentanyl analog.12. The patch of wherein said adhesive has a Tless than −10° C.; and fentanyl as ...

IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY

Endothelialization of a bodily fluid or tissue-contacting, particularly blood-contacting, surface may be accomplished to render that surface substantially non-thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue. 1. An implantable device comprising:at least one first degradable layer providing at least one surface of the implantable device for contacting bodily fluid or tissue and disposed about a central core; andat least one second degradable layer between said first degradable layer and the central core, wherein said first degradable layer has a first degradation rate and said second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly then said at least one second degradable layer on contact with bodily fluid or tissue.2. The implantable device of claim 1 , wherein the first degradable layer comprises a different material than the second degradable layer.3. The implantable device of claim 1 , wherein the second degradable layer comprises PLA and the first degradable layer comprises PLGA.4. The implantable device of claim 1 , wherein the first degradable layer comprises a polymer selected from the group consisting of PLGA 80/20 claim 1 , PLGA 75/25 claim 1 , and PLGA 53/47. ...

IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY

Endothelialization of a bodily fluid or tissue-contacting, particularly blood-contacting, surface may be accomplished to render that surface substantially non-thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue.

NANOLIPOSOMES COMPRISING CORTICOSTEROID AS MEDICAMENTS AND METHODS TO PREPARE THEM

Nanoliposomes comprising at least one outer lipid bilayer and at least one corticosteroid encapsulated by the at least one lipid bilayer are provided. Uses of the nanoliposomes as a medicament and in the treatment of a cardiovascular disease are also provided. Further, methods of preparing the nanoliposomes are additionally provided. 1. A nanoliposome comprising at least one outer lipid bilayer and at least one corticosteroid encapsulated by the at least one lipid bilayer.2. The nanoliposome according to claim 1 , wherein the ratio of the at least one corticosteroid and the lipids forming the at least one lipid bilayer is between 0.01 and 0.5.3. The nanoliposome according to claim 1 , wherein the ratio of the at least one corticosteroid and the lipids forming the at least one lipid bilayer is between 0.1 and 0.3.4. The nanoliposome according to claim 1 , wherein the ratio of the at least one corticosteroid and the lipids forming the at least one lipid bilayer is between 0.12 and 0.18.5. The nanoliposome according to claim 1 , wherein the size of the liposome is between 10 nm to 1000 nm claim 1 , preferably between 50 nm to 150 nm.6. The nanoliposome according to claim 1 , wherein the at least one lipid bilayer comprises at least two different types of lipids.7. The nanoliposome according to claim 1 , wherein the lipids forming the at least one lipid bilayer are modified by polyethylene glycol (PEG) and/or the at least one lipid bilayer comprises non-coupled polyethylene glycol (PEG).8. The nanoliposome according to claim 1 , wherein lipids of the at least one lipid bilayer are selected from the group consisting of phosphocholines and sphingolipids.9. The nanoliposome according to claim 1 , wherein lipids of the at least one lipid bilayer are selected from the group consisting of dipalmitoylphosphatidylcholin (DPPC) claim 1 , 1 claim 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) claim 1 , sphingomyelin claim 1 , N-[1-(2 claim 1 ,3-Dioleoyloxy)propyl]-N ...

FORMULATIONS OF 5-HYDROXY TRYPTOPHAN (5-HTP) FOR BETTER BIOAVAILABILITY FOR VARIOUS INDICATIONS

Disclosed herein are a range of gastroretentive sustained release dosage forms that may be particularly useful in the delivery of 5-HTP and other agents that would benefit from delivery to the upper gastrointestinal tract.

NANOLIPOSOMES FOR SUSTAINED DELIVERY OF TACROLIMUS FOR TREATMENT OF ANTERIOR SEGMENT EYE DISEASES

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

PHOTODYNAMICALLY ACTIVE ORGANOSILICA NANOPARTICLES AND MEDICAL USES THEREOF

The present application provides an organosilica nanoparticle comprising: (a) a photosensitizer for photodynamic therapy covalently incorporated therein; and (b) optionally, at least one agent encapsulated therein, as well as a pharmaceutical composition comprising said organosilica nanoparticle. Also provided herein are said organosilica nanoparticle or pharmaceutical composition for use as a medicament or in the treatment of a disease, disorder, or condition. More specifically, provided is a method for treating a disease, disorder, or condition in a subject using said aid organosilica nanoparticle or pharmaceutical composition.

BIOREACTOR MODULE, A BIOREACTOR SYSTEM AND METHODS FOR THICK TISSUE SEEDING AND CULTIVATION IN AN HIERARCHICAL ORGANIZATION AND PHYSIOLOGICAL MIMICKING CONDITIONS

According to various embodiments, there is provided a bioreactor module including a container; a holder removably receivable in the container, the holder adapted to hold a scaffold containing an inherent vascular network; an inlet connectable to a vessel of the inherent vascular network of the scaffold; an inflatable device disposed substantially near a base of the container, the inflatable device having a conduit extending through a wall of the container; and a pair of electrodes attached to opposing walls of the container. 1. A bioreactor module comprising:a container;a holder removably receivable in the container, the holder including any one of a clamping mechanism, a gripping mechanism, a hook, or an attachment mechanism configured to hold a scaffold containing an inherent vascular network;an inlet connectable to a vessel of the inherent vascular network of the scaffold;an inflatable device disposed within the container, the inflatable device having a conduit extending through a wall of the container; anda pair of electrodes attached to opposing walls of the container.2. The bioreactor module as claimed in claim 1 , further comprising an outlet in a wall of the container.3. The bioreactor module as claimed in claim 1 , further comprising a transparent window covering an opening of the container.4. The bioreactor module as claimed in claim 1 , wherein the holder comprises a pair of holders positioned in the container in a spaced apart configuration claim 1 , and wherein the pair of holders is configured such that a distance between the holders is variable.5. The bioreactor module as claimed in claim 1 , wherein the scaffold comprises a natural scaffold containing a natural inherent vascular network or a synthetic scaffold containing an inherent vascular network formed in the synthetic scaffold.6. The bioreactor module as claimed in claim 1 , wherein an end of the vessel of the inherent vascular network of the scaffold is opened.7. A bioreactor system comprising ...

LIPOSOMAL FORMULATIONS

According to the present disclosure, a liposomal formulation comprising at least one uncharged phospholipid without cholesterol and at least one pharmaceutical agent, wherein the at least one uncharged phospholipid forms one or more lipid bilayers without cholesterol encapsulating the at least one pharmaceutical agent, is provided. The use(s) of such a liposomal formulation and method of producing such a liposomal formulation are also provided.

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

Transdermal Administration Of Fentanyl And Analogs Thereof

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

BIODEGRADABLE OCULAR IMPLANT

Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Targetted drug delivery to the bone

The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.

Occlusion device for closing anatomical defects

The present invention generally relates to the field of transcatheter device closure techniques for closing an opening in a tissue and more particularly, to occlusion devices for closing anatomical defects in tissue. More particularly the present invention refers to occlusion devices for closing septal abnormalities such as atrial septal defects and patent foramen ovale, and to methods of closing an anatomical defect in a tissue.

OCCLUSION DEVICE FOR CLOSING ANATOMICAL DEFECTS

The present invention generally relates to the field of transcatheter device closure techniques for closing an opening in a tissue and more particularly, to occlusion devices for closing anatomical defects in tissue such as defects consisting of an opening connecting a front side and a back side of a tissue. More particularly the present invention relates to occlusion devices for closing septal abnormalities such as atrial septal defects and patent foramen ovale, delivering systems for such occlusion devices, kits comprising the occlusion devices and the delivering systems and to methods of closing an anatomical defect in a tissue consisting of an opening connecting a front side and a back side of a tissue. 1. An occlusion device for closing an anatomical defect in tissue comprising an opening connecting a front side and a back side of a tissue , wherein the occlusion device is adapted to be included into a sheath of a catheter , and the occlusion device comprises: a head tube positioned at an anterior end of the scaffold,', 'a tail tube positioned at a posterior end of the scaffold; wherein the head tube and the tail tube are movable along the direction towards and away from each other, and', 'an engaging means connected to the head tube and being adapted to be engagable at the tail tube, and, '(i) a scaffold comprising a foldable head portion which is connected at one end to the head tube and being adapted to be disposed together with the head tube at the front side of the defect,', 'a foldable tail portion which is connected to one end of the tail tube and being adapted to be disposed together with the tail tube at the back side of the defect, and', 'a waist portion adapted to extend through the opening of the defect and being arranged between the foldable head portion and the foldable tail portion,, '(ii) a foldable section comprisingwherein each of the foldable head portion and the foldable tail portion comprises two or more arms extending between the head tube ...

Biodegradable ocular implant

The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

GLAUCOMA VALVE, A CASING FOR CONTAINING A GLAUCOMA VALVE, AND A GLAUCOMA DRAINAGE DEVICE COMPRISING THE VALVE AND/OR THE CASING

Various embodiments of the invention relate to a glaucoma valve, a casing for containing a glaucoma valve and a glaucoma drainage device comprising the glaucoma valve and/or the casing. The valve includes a flow channel having an inlet and an outlet and a valve member connected to the outlet of the flow channel. The valve member may be formed from a degradable polymer or a combination of degradable polymer and non-degradable polymer. Various embodiments of the invention relate to a glaucoma valve, the valve having a first flow channel. The interior of the first flow channel may be coated with a degradable polymer, such that in use, the polymer degrades to allow a greater flow of fluid through the flow channel. In some embodiments, the valve includes a second flow channel, which may be arranged in parallel to the first flow channel. The first flow channel may be completely sealed with the polymer such that in use, the polymer degrades to allow fluid to flow through the first flow channel. Various embodiments relate to a casing for containing a glaucoma valve. The casing may be formed from a degradable polymer, such as a biodegradable polymer. 1. A glaucoma valve , the valve comprisinga) a flow channel having an inlet and an outlet; andb) a valve member connected to the outlet of the flow channel, wherein the valve member comprises a degradable polymer and a steroid.2. The glaucoma valve according to claim 1 , wherein the polymer is a biodegradable elastomer.3. The glaucoma valve according to claim 2 , wherein the biodegradable elastomer is selected from the group consisting of polylactic acid (PLA) claim 2 , polycaprolactone (PCL) claim 2 , poly(glycolide) (PLGA) claim 2 , a copolymer of PLA and PCL claim 2 , a copolymer of PLA claim 2 , PCL and PLGA claim 2 , a copolymer of PLA claim 2 , PCL and trimethylene carbonate (TMC) claim 2 , a copolymer of PLA claim 2 , PCL claim 2 , TMC and polyurethane (PU).4. The glaucoma valve according to claim 3 , wherein the ...

LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY

The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2μπι. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof. 1. A liposomal formulation for ocular drug delivery comprising:(i) liposomes comprising at least one lipid bilayer; and wherein the liposomes have a mean diameter of less than 2 μm; and', 'wherein the liposomes comprise phosphatidylcholines., '(ii) a prostaglandin drug and/or a prostaglandin derivative encapsulated in the liposomes,'}2. The liposomal formulation as claimed in claim 1 , wherein the liposomes comprise mixtures of phosphatidylcholines and at least one of sphingolipids claim 1 , sterol lipids claim 1 , saccharolipids claim 1 , or polyketide lipids.35.-. (canceled)6. The liposomal formulation as claimed in claim 1 , wherein the phosphatidylcholines each comprises at least one unsaturated fatty acid moiety.7. The liposomal formulation as claimed in claim 6 , wherein the phosphatidylcholines each comprises L-α-phosphatidylcholine or 95% Egg phosphatidylcholines (EPC).8. The liposomal formulation as claimed in claim 2 , wherein the sphingolipids each comprises at least one unsaturated fatty acid moiety.9. The liposomal formulation as claimed in claim 8 , wherein the sphingolipids each comprises hexadecanoylsphingomyelin or Egg Sphingomyelin.1011.-. (canceled)12. The liposomal formulation as claimed in claim 1 , wherein the prostaglandin drug comprises latanoprost.1316.-. ...

DEVICE FOR CONTROLLED RELEASE OF A BIOACTIVE AGENT

Present invention relates to a device for controlled release of a bioactive agent. The device comprises a thin film located on the surface of the device, wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent. 1. A device for controlled release of a bioactive agent , the device comprising a thin film located on the surface of the device , wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent.2. The device of claim 1 , wherein the polymeric matrix of the bioactive agent-containing layer comprises a polymer selected from the group consisting of polyethylene glycol (PEG) claim 1 , PEG fatty acid esters claim 1 , poly-L-lactic acid (PLLA) claim 1 , poly(lactide-co-glycolide) (PLGA) claim 1 , poly caprolactone (PCL) claim 1 , polyvinyl pyrrolidone (PVP) claim 1 , polyvinyl alcohol (PVA) claim 1 , collagen claim 1 , chitosan claim 1 , hydroxy propyl cellulose claim 1 , polyamides claim 1 , polyglycerol esters of fatty acids claim 1 , and combinations thereof.3. The device of claim 2 , wherein the polymeric matrix comprises PLGA and PEG.4. The device of or claim 2 , wherein the polymeric matrix comprises between 0 and 50% by weight PEG with the balance being PLGA.54. The device of any one of - claims 2 , wherein the PEG has a molecular weight of between 0.4 kDa and 500 kDa.6. The device of claim 2 , wherein the polymeric matrix comprises PEG fatty acid esters.7. The device of claim 6 , wherein the PEG fatty acid ester is PEG distearate.8. The device of or claim 6 , further comprising one or more fatty acids or fatty alcohols.98. The device of any one of - claims 6 , wherein the polymeric matrix comprises 50 to 99% by weight 400 Da PEG distearate and 1 to 50% cetyl alcohol.109. The device of any one of - claims 1 , wherein the polymeric matrix of the bioactive agent-containing layer is biodegradable.1110. The device of any ...

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. 1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmor contains sufentanil and has an area of 0.5 to 40 cm.3. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmand contains no permeation enhancer.4. The patch of wherein said patch exhibits a normalized Cof 3.3 to 82.5 ng/(ml(mg/h)).5. The patch of wherein the patch exhibits a steady state drug flux of 0.1 to 20 μg/(cmhr).6. The patch of wherein said patch exhibits a standardized Cof 0.001 to 0.2 ng/(ml-cm).7. The patch of wherein the reservoir contains sufentanil and has an area of 0.5 to 40 cm.8. The patch of wherein said reservoir comprises an amount of dissolved fentanyl analog sufficient to induce and maintain analgesia for 3-7 days.9. The patch of wherein said fentanyl analog is selected from the group consisting of alfentanil claim 8 , lofentanil claim 8 , remifentanil and sufentanil.10. The patch of wherein said reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of 1 wt % to 25 wt %.11. The patch of wherein the reservoir comprises 0.05 to 1.75 mg/cmof fentanyl analog.12. The patch of wherein said adhesive has a Tless than −10° C.; and fentanyl has a ...

BIOABSORBABLE TRACHEAL STENT, AND METHOD OF MANUFACTURING THEREOF

A bioabsorbable tracheal stent is provided. The bioabsorbable stent comprises a biodegradable polymer, wherein the “ biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. A drug is dispersed within or dissolved in the biodegradable polymer. In a second and third aspect, the invention relates to methods of manufacturing a bioabsorbable tracheal stent. The first method includes forming a solution comprising a biodegradable polymer and a drug, the biodegradable polymer comprising about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. The method further comprises casting the solution to form the bioabsorbable tracheal stent. The second method includes forming a polymeric stent, and dip casting the polymeric stent in a solution comprising a biodegradable polymer and a drug to form a coating on the polymeric stent, wherein the biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. 1. A bioabsorbable tracheal stent comprisinga) a biodegradable polymer comprising about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or a mixture thereof; andb) a drug dispersed within or dissolved in the biodegradable polymer.2. (canceled)3. The bioabsorbable tracheal stent according to claim 1 , wherein the biodegradable polymer is a copolymer of poly(L-lactide) and poly(caprolactone).4. The bioabsorbable tracheal stent according to claim 3 , wherein the weight ratio of poly(L-lactide) to poly(caprolactone) in the copolymer is about 1:1 to about 9:1.5. The bioabsorbable tracheal stent according to claim 4 , wherein the weight ratio of poly(L-lactide) to poly(caprolactone) in the copolymer is about 7:3.6. (canceled)7. The bioabsorbable tracheal stent according to claim 1 , wherein the drug is mitomycin C.8. The bioabsorbable tracheal stent according to claim 1 , wherein the biodegradable polymer forms the body of the ...

Method for preparing a patterned substrate and use thereof in implants for tissue engineering

A method for preparing a patterned substrate is provided. The method includes melt-spinning at least one biocompatible polymer to form fibers; collecting the fibers on a substrate such that the fibers are aligned on the substrate; and applying a binding agent to the aligned fibers to bond the fibers into the aligned arrangement to obtain the patterned substrate in form of an aligned fiber mat. Use of the patterned substrate in an implant for tissue engineering is also provided.

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. 1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmor contains sufentanil and has an area of 0.5 to 40 cm.3. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmand contains no permeation enhancer.4. The patch of wherein said patch exhibits a normalized Cof 3.3 to 82.5 ng/(ml(mg/h)).5. The patch of wherein the patch exhibits a steady state drug flux of 0.1 to 20 μg/(cmhr).6. The patch of wherein said patch exhibits a standardized Cof 0.001 to 0.2 ng/(ml-cm).7. The patch of wherein the reservoir contains sufentanil and has an area of 0.5 to 40 cm.8. The patch of wherein said reservoir comprises an amount of dissolved fentanyl analog sufficient to induce and maintain analgesia for 3-7 days.9. The patch of wherein said fentanyl analog is selected from the group consisting of alfentanil claim 8 , lofentanil claim 8 , remifentanil and sufentanil.10. The patch of wherein said reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of 1 wt % to 25 wt %.11. The patch of wherein the reservoir comprises 0.05 to 1.75 mg/cmof fentanyl analog.12. The patch of wherein said adhesive has a Tless than −10° C.; and fentanyl has a ...

OPTICAL CYLINDER AND METHOD OF SURFACE TREATMENT OF THE SAME

Disclosed is an optical cylinder of a corneal prosthesis comprising: a) an optical cylinder comprising a solid polymer, and b) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder. Also disclosed are methods of surface treatment of optical cylinders of corneal prostheses, and corneal prostheses thereof. 1. An optical cylinder of a corneal prosthesis comprising:a) an optical cylinder comprising a solid polymer, andb) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder.2. The optical cylinder of claim 1 , wherein the solid polymer is optically transparent.3. The optical cylinder of claim 1 , wherein the solid polymer is selected from the group consisting of poly(methyl methacrylate) (PMMA) claim 1 , polystyrene claim 1 , polycarbonate claim 1 , polythiourethane claim 1 , polyethylene terephthalate claim 1 , and polypropylene.4. The optical cylinder of claim 1 , wherein the solid polymer is poly(methyl methacrylate) (PMMA).5. The optical cylinder of claim 1 , wherein the nanoparticle covers at least 70% of the circumference of the solid polymer surface of the optical cylinder.6. The optical cylinder of claim 1 , wherein the Root Mean Square (RMS) roughness (R) value of the layer is from 150 nm to 80 nm.7. The optical cylinder of claim 1 , wherein the thickness of the layer is from 30 μm to 100 μm.8. The optical cylinder of claim 1 , wherein the nanoparticle is insoluble in organic solvent.9. The optical cylinder of claim 1 , wherein the nanoparticle is selected from the group consisting of bioceramic nanoparticle claim 1 , metal nanoparticle claim 1 , and a mixture thereof.10. The optical cylinder of claim 1 , wherein the nanoparticle is a bioceramic nanoparticle selected from the group consisting of hydroxyapatite (HAp) nanoparticle claim 1 , titanium oxide (TiO) nanoparticle claim 1 , aluminum ...

STABLE LIPOSOMAL FORMULATIONS FOR OCULAR DRUG DELIVERY

A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation. 1. A stable liposomal formulation for ocular delivery , the formulation comprising a liposome including at least one lipid bilayer that contains a phosphatidylcholine , and a prostaglandin F encapsulated in the liposome , wherein the liposome has a diameter of less than 2 μm.2. The stable liposomal formulation of claim 1 , wherein the phosphatidylcholine is palmitoyl oleoyl phosphatidyl choline (POPC).3. The stable liposomal formulation of claim 2 , wherein the prostaglandin F is latanoprost claim 2 , bimatoprost claim 2 , travoprost claim 2 , or carboprost.4. The stable liposomal formulation of claim 3 , wherein the prostaglandin F is latanoprost.5. The stable liposomal formulation of claim 4 , wherein the formulation has a mole ratio of latanoprost to POPC of 0.01:1 to 0.5:1.6. The stable liposomal formulation of claim 5 , wherein the mole ratio of latanoprost to POPC is 0.01:1 to 0.175:1.7. The stable liposomal formulation of claim 5 , wherein the liposome has a diameter of 100 nm to 300 nm.8. The stable liposomal formulation of claim 6 , wherein the liposome has a diameter of 100 nm to 300 nm.9. A method for treating an ocular disorder claim 1 , comprising administering to an eye of a subject in need thereof the formulation of .10. The method of claim 9 , wherein the ocular disorder is ocular hypertension or glaucoma.11. The method of claim 10 , wherein the formulation is administered via subconjunctival injection.12. A method for treating an ocular disorder claim 7 , comprising administering to an eye of a subject in need thereof the formulation of .13. The method of claim 12 , wherein the ocular disorder is ocular hypertension or glaucoma.14. The method of claim 13 , ...

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. 1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmor contains sufentanil and has an area of 0.5 to 40 cm.3. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmand contains no permeation enhancer.4. The patch of wherein said patch exhibits a normalized Cof 3.3 to 82.5 ng/(ml(mg/h)).5. The patch of wherein the patch exhibits a steady state drug flux of 0.1 to 20 μg/(cmhr).6. The patch of wherein said patch exhibits a standardized Cof 0.001 to 0.2 ng/(ml-cm).7. The patch of wherein the reservoir contains sufentanil and has an area of 0.5 to 40 cm.8. The patch of wherein said reservoir comprises an amount of dissolved fentanyl analog sufficient to induce and maintain analgesia for 3-7 days.9. The patch of wherein said fentanyl analog is selected from the group consisting of alfentanil claim 8 , lofentanil claim 8 , remifentanil and sufentanil.10. The patch of wherein said reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of 1 wt % to 25 wt %.11. The patch of wherein the reservoir comprises 0.05 to 1.75 mg/cmof fentanyl analog.12. The patch of wherein said adhesive has a Tless than −10° C.; and fentanyl has a ...

DRUG ELUTING MEMBER, A METHOD OF ATTACHING THE SAME AND A METHOD OF FABRICATING THE SAME, A DEVICE FOR HOLDING THE SAME AND A DRUG ELUTING DEVICE

A drug eluting member is adapted to be attachable onto a perimeter edge of a lens portion of an intraocular lens, the drug eluting member including an interfacing portion adapted to receive a portion of the perimeter edge. A drug eluting device includes a first and second drug eluting members adapted to be attached to first and second portions, respectively of the perimeter edge. A method attaches the drug eluting member to the perimeter edge by positioning a holding device with the drug eluting member held therein against a portion of the perimeter edge; and releasing the drug eluting member from the holding device portion. A method of fabricating the drug eluting member includes providing a mold for molding the drug eluting member; discharging a forming solution from a nozzle onto the mold; and forming the drug eluting member. 1. A drug eluting member adapted to be attachable onto a perimeter edge of a lens portion of an intraocular lens , the drug eluting member comprising:an interfacing portion adapted to receive a portion of the perimeter edge.2. The drug eluting member of claim 1 , wherein the interfacing portion comprises a channel adapted to receive the portion of perimeter edge therein.3. The drug eluting member of claim 2 , wherein the channel conforms to the profile of the portion of the perimeter edge.4. The drug eluting member of claim 1 , wherein the interfacing portion comprises an adhesive surface adapted to adhere the drug eluting member to the lens portion.5. The drug eluting member of claim 1 , wherein the drug eluting member is bio-degradable.6. The drug eluting member of claim 1 , wherein the drug eluting member is arcuated.7. The drug eluting member of claim 1 , wherein the drug eluting member surrounds the lens portion along the perimeter edge of the lens portion.8. The drug eluting member of claim 1 , wherein the drug eluting member is ring-shaped.9. A drug eluting device comprising a first drug eluting member and a second drug eluting member ...

OCCLUSION DEVICE FOR CLOSING ANATOMICAL DEFECTS

An occlusion device for closing an anatomical defect in tissue comprising a conduit connecting an opening on a first tissue and an opening on a second tissue is provided. The occlusion device comprises a scaffold comprising a) a proximal support structure comprising at least two arms; b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the device in the tissue; and c) a waist portion adapted for extending through the opening on the first tissue and connecting the proximal support structure with the distal support structure, wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise or consist of polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof. A method of closing an anatomical defect using the occlusion device is also provided. 1. An occlusion device for closing an anatomical defect in tissue that includes a conduit connecting an opening on a first tissue and an opening on a second tissue , the occlusion device comprising a scaffold that includes:a) a proximal support structure comprising at least two arms;b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the distal support structure within the conduit; andc) a waist portion configured to extend through the opening on the first tissue and connect the proximal support structure with the distal support structure,wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof.2. The occlusion device according to claim 1 , wherein the scaffold further comprises a proximal occlusion film supported by the proximal support structure.3. The occlusion device according to claim 1 , wherein the at least ...

HYALURONIC ACID-BASED DRUG DELIVERY SYSTEMS

The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions. 1. A hyaluronic acid (HA) hydrogel comprising loaded vesicles dispersed thereinwherein the loaded vesicles are loaded with one or more drugs, one or more proteins, or one or more nucleic acids.2. The HA hydrogel of claim 1 , wherein the loaded vesicles are selected from micelles claim 1 , liposomes and/or particles selected from nanoparticles and microparticles.3. The HA hydrogel according to claim 1 , wherein the micelles are made of amphipilic self-assembling molecules.4. The HA hydrogel according to claim 1 , wherein the vesicles are liposomes.5. The HA hydrogel according to wherein the self-assembling molecules are selected from polymers and surfactants claim 1 , preferably block copolymer claim 1 , more preferably Pluronic block copolymer.6. The HA hydrogel according to wherein the particles are selected from chitosan nanoparticles claim 1 , chitosan microparticles claim 1 , poly(lactic-co-glycolic acid) (PLGA) nanoparticles and poly(lactic-co-glycolic acid) (PLGA) microparticles.7. The HA hydrogel according to claim 1 , wherein the drug is selected from a hydrophobic or hydrophilic drug claim 1 , preferably is selected from an antibiotic drug claim 1 , a chemio-therapeutic drug claim 1 , a drug for the treatment of glaucoma or ocular hypertension such as latanoprost or 5-flurouracil (5-FU) claim 1 , the protein is selected from therapeutic peptide or protein or monoclonal antibodies claim 1 , anti-VEGF antibodies such as bevacizumab and ranibizumab claim 1 , the nucleic acid is selected from siRNA and plasmid DNA.8. The HA hydrogel according ...

SUSTAINED TIMOLOL MALEATE DELIVERY FROM LIPOSOMES FOR GLAUCOMA THERAPY AND OCCULAR HYPERTENSION

Various embodiments relate to the field of liposomal formulations for drug delivery, in particular, liposomal formulations for ocular drug delivery. More specifically, various embodiments relate to sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension. 1. Liposomal formulation for ocular drug delivery , comprising: (a) wherein one or more of the lipid bilayers are comprised of a mixture of 50-80 mol % of a lipid and 20-50 mol % of a steroid alcohol, wherein the lipid is comprised of glyceride, phosphatidylcholine, and/or sphingolipid; or', '(b) wherein the one or more lipid bilayers are comprised of a mixture of 50-80 mol % of a neutral lipid and 20-50 mol % of a charged lipid, wherein the neutral lipid and the charged lipid are comprised of glyceride, phosphatidylcholine, and/or sphingolipid., 'liposomes each comprising a core surrounded by one or more lipid bilayers, and timolol maleate comprised in the core of each liposome,'}2. Liposomal formulation according to claim 1 , wherein the one or more lipid bilayers are comprised of 30-50 mol % of the steroid alcohol claim 1 , preferably 30 mol % claim 1 , 35 mol % claim 1 , 37 mol % claim 1 , 40 mol % claim 1 , 45 mol % claim 1 , or 50 mol %.3. Liposomal formulation according to or claim 1 , wherein the steroid alcohol comprises phytosterol claim 1 , zoosterol claim 1 , or a mixture thereof.6. Liposomal formulation according to any one of the preceding claims claim 1 , wherein the lipid and/or the neutral lipid comprises one of phosphatidylcholine and sphingolipids.7. Liposomal formulation according to claim 6 , wherein the phosphatidylcholine is selected from the group consisting of 1 claim 6 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) claim 6 , 1 claim 6 ,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) claim 6 , 1 claim 6 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) claim 6 , 1 claim 6 ,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) claim 6 , 1 claim 6 ,2-distearoyl ...

NATRIURETIC POLYPEPTIDE DELIVERY SYSTEMS

This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided. 112-. (canceled)13. A method for treating a mammal to increase plasma natriuretic polypeptide levels and plasma cGMP levels in said mammal , wherein said method comprises administering a polymer gel composition to said mammal , wherein said polymer gel composition comprises a natriuretic polypeptide , poly(lactic-co-glycolic acid) , N-methyl-2-pyrrolidinone , and triacetin , wherein the poly(lactic-co-glycolic acid) of said composition has an intrinsic viscosity between 0.3 and 3 dL/g , and wherein said natriuretic polypeptide is released from said polymer gel composition into the circulation of said mammal over a period of time greater than 2 weeks following administration of said polymer gel composition to said mammal.14. The method of claim 13 , wherein mammal is a human.15. The method of claim 13 , wherein said natriuretic polypeptide is CD-NP.16. The method of claim 13 , wherein said natriuretic polypeptide comprises the amino acid sequence set forth in one of SEQ ID NOs:1-10.17. The method of claim 13 , wherein said polymer gel composition comprises from about 0.1 percent and 0.5 percent of said natriuretic polypeptide by weight.18. The method of claim 13 , wherein said polymer gel composition comprises from about 15 percent and 45 percent of said poly(lactic-co-glycolic acid) by weight.19. The method of claim 13 , wherein said polymer gel composition comprises from about 15 percent and 25 percent of the poly(lactic-co-glycolic acid) by weight.20. The method of claim 13 , wherein said polymer gel composition comprises from about 1 percent and 10 percent of ...

MULTILAYERED NANOPARTICLE AND METHODS OF MANUFACTURING AND USING THE SAME

The invention relates to a multilayered nanoparticle for delivery of RNA to a cell and methods of manufacturing and using the same. The multilayered nanoparticle has a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the at least one of the negatively charged polymer layers is RNA. 1. Multilayered nanoparticle for delivery of RNA to a cell , the nanoparticle comprising: a core nanoparticle coated by alternating positively and negatively charged polymer layers , wherein the number of layers is 2 or more and wherein at least one of the negatively charged polymer layers comprises or consist of RNA.2. The multilayered nanoparticle according to claim 1 , wherein the RNA is selected from the group consisting of ribozymes claim 1 , RNAi and the siRNA.3. The multilayered nanoparticle according to or claim 1 , wherein the nanoparticle core is biocompatible or biodegradable.4. The multilayered nanoparticle according to any one of - claim 1 , wherein the nanoparticle core comprises or consists of a material selected from the group consisting of hydroxyapatite claim 1 , silica claim 1 , poly(lactide-co-glycolide) (PLGA) claim 1 , poly(lactic acid) (PLA) claim 1 , calcium carbonate claim 1 , gold claim 1 , polystyrene latex claim 1 , preferably hydroxyapatite.5. The multilayered nanoparticle according to any one of - claim 1 , wherein the nanoparticle core comprises a liposome.6. The multilayered nanoparticle according to any one of - claim 1 , wherein the nanoparticle core is negatively charged.7. The multilayered nanoparticle according to any one of - claim 1 , wherein the multilayered nanoparticle comprises 3 to 10 layers.8. The multilayered nanoparticle according to any one of - claim 1 , wherein the outermost layer of the polymer layers is a positively charged polymer layer.9. The multilayered nanoparticle according to any one of - claim 1 , wherein the innermost layer of the polymer layers is a positively charged polymer ...

TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. 1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir being 0.0125 mm to 0.1 mm thick, comprising a single phase polymeric composition free of undissolved fentanyl or an analog thereof and containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmor contains sufentanil and has an area of 0.5 to 40 cm.3. The patch of wherein the reservoir contains fentanyl and has an area of 1 to 150 cmand contains no permeation enhancer.4. The patch of wherein said patch exhibits a normalized Cof 3.3 to 82.5 ng/(ml(mg/h)).5. The patch of wherein the patch exhibits a steady state drug flux of 0.1 to 20 μg/(cmhr).6. The patch of wherein said patch exhibits a standardized Cof 0.001 to 0.2 ng/(ml−cm).7. The patch of wherein the reservoir contains sufentanil and has an area of 0.5 to 40 cm.8. The patch of wherein said reservoir comprises an amount of dissolved fentanyl analog sufficient to induce and maintain analgesia for 3-7 days.9. The patch of wherein said fentanyl analog is selected from the group consisting of alfentanil claim 8 , lofentanil claim 8 , remifentanil and sufentanil.10. The patch of wherein said reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of 1 wt % to 25 wt %.11. The patch of wherein the reservoir comprises 0.05 to 1.75 mg/cmof fentanyl analog.12. The patch of wherein said adhesive has a Tless than −10° C.; and fentanyl has a ...

Bio-Absorbable Medicament-Eluting Ventilation Tube

The present disclosure relates to ventilation tubes used in the treatment of aural maladies such as, for example, otitis media. A bio-absorbable ventilation tube, optionally containing a medicament, is described for use in a land mammal. The bio-absorbable ventilation tube can be customized for both specific treatment and specific degradation rate based in part on the quantity and type of medicament added to a polymer forming the bio-absorbable ventilation tube. A method of preparing the bio-absorbable ventilation tube of the present disclosure is also provided. 1. A bio-absorbable ventilation tube comprising:a bio-absorbable co-polymer; anda medicament,wherein about 80% of said medicament releases from said bio-absorbable polymer in about 90 days.2. The bio-absorbable ventilation tube of claim 2 , wherein the bio-absorbable co-polymer comprises polylactic acid and poly-ε-caprolactone.3. The bio-absorbable ventilation tube of claim 1 , wherein the medicament is selected from the group consisting of antibiotics claim 1 , anti-inflammatory agents claim 1 , and biologics.4. The bio-absorbable ventilation tube of claim 1 , wherein the bio-absorbable ventilation tube has an outer flange diameter of from about 1.25 mm to about 2.1 mm.5. The bio-absorbable ventilation tube of claim 1 , wherein the bio-absorbable ventilation tube has an inner diameter of from about 0.7 mm to about 1.14 mm.6. The bio-absorbable ventilation tube of claim 3 , wherein the medicament is an antibiotic selected from the group consisting of erythromycin claim 3 , azithromycin claim 3 , clarithromycin claim 3 , ofloxacin claim 3 , levofloxacin claim 3 , ciprofloxacin claim 3 , sulfadimidine claim 3 , and tetracycline.7. The bio-absorbable ventilation tube of claim 3 , wherein the medicament is a biologic selected from the group consisting of human serum albumin and collagen.8. The bio-absorbable ventilation tube of claim 1 , wherein the medicament comprises from about 0.1 wt. % to about 50 wt. % of ...

A DEVICE AND METHOD FOR FORMING AN ANASTOMOTIC JOINT BETWEEN TWO PARTS OF A BODY

A device and method for forming an anastomotic joint between two parts of a human or animal body having a hollow connector with at least two proximal arms biased towards an open position; and at least two distal arms biased towards an open position, wherein in use when pressure is applied to the proximal arms to overcome the bias into a position in which the proximal arms are closer to each other; similarly pressure is applied to the distal arms to overcome the bias into a position in which the distal arms are closer to each other; the distal end can be pushed into a passage in the first human or animal body part until the distal arms are located in the first lumen of the first body part and released allowing the distal arms to move to the biased position to urge against the first lumen of the first body part; and the proximal end can be pushed into a passage in the second human or animal body part until the proximal arms are located in the second lumen of the second body part and released allowing the proximal arms to move to the biased position to urge against the second lumen of the second body part. 1. A device for forming an anastomotic joint between two parts of a human or animal body comprising: a hollow connector having connected near a proximal end of the connector at least two proximal arms each of which has a free end , wherein at least portions including the respective free ends of these at least two proximal arms are movable or rotatable or foldable with regard to each other between positions in which the free ends of said proximal arms are closer to each other and positions in which the distance between the free ends of said proximal arms is comparably larger , and wherein these at least two proximal arms are biased towards respective directions in which the respective free ends of said proximal arms are movable to respective positions in which the distance between said free ends of said proximal arms is enlarged , so that the proximal arms are ...

Transdermal administration of fentanyl and analogs thereof

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

TRANSDERMAL PATCH TO ADMINISTER FENTANIL.

Un parche transdérmico para administrar fentanilo, alfentanilo, carfentanilo, lofentanilo, remifentanilo, sufentanilo o trefentanilo a través de la piel, que comprende: (a) una capa de refuerzo; (b) un depósito colocado en la capa de refuerzo, siendo adhesiva al menos la superficie de contacto con la piel de dicho depósito; comprendiendo dicho depósito una composición polimérica de una única fase libre de componentes no disueltos que contiene una cantidad de un fármaco seleccionado entre el grupo compuesto por fentanilo, alfentanilo, carfentanilo, lofentanilo, remifentanilo, sufentanilo y trefentanilo suficiente para inducir y mantener analgesia en un ser humano durante al menos tres días; caracterizado porque el depósito está formado de un adhesivo de poliacrilato y tiene un grosor de 0, 0125 mm (0, 5 mil) a 0, 1 mm (4 mil). A transdermal patch for administering fentanyl, alfentanil, carfentanil, lofentanil, remifentanil, sufentanil or trefentanil through the skin, comprising: (a) a reinforcing layer; (b) a deposit placed in the reinforcement layer, at least the skin contact surface of said deposit being adhesive; said reservoir comprising a single phase polymer composition free of undissolved components containing an amount of a drug selected from the group consisting of fentanyl, alfentanil, carfentanil, lofentanil, remifentanil, sufentanil and trefentanil sufficient to induce and maintain analgesia in a being human for at least three days; characterized in that the tank is formed of a polyacrylate adhesive and has a thickness of 0.0125 mm (0.5 mil) to 0.1 mm (4 mil).

Implantable article, method of forming same and method for reducing thrombogenicity

Endothelialization of a bodily fluid or tissue-contacting, particularly blood-contacting, surface may be accomplished to render that surface substantially non-thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue.

Device for controlled release of a bioactive agent

Present invention relates to a device for controlled release of a bioactive agent. The device comprises a thin film located on the surface of the device, wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent.

Multi-level automated storage for over-dimensional and bulky objects

The present invention, a system for storing and retrieving over-dimensional and heavy objects precisely directed towards containers (16) comprising plurality of storage tiers (2) with storage addressed slots (3) on either side of a central causeway with fixed first track on it; at least one elevator (4) to serve as input cum output device and its orientation transverse to the line of storing to maintain unidirectional receipt and delivery; at least one independently driven transfer module (5) in each tier moving on a said fixed first track along the length of the tier to move the objects along the line of stacking; each transfer module (5) has an independently driven power arm (8) moving on a fixed second track along the length of the transfer module (5) and transverse to the line of storing and at a lower elevation than the fixed first track to push/pull the objects into/out of the elevator (4) and storage slots (3) and this power arm (8) is with its lifting means and electromagnetic coupling and decoupling arrangement to facilitate pushing and pulling in desired direction, at least one row of spherical balls or rollers along the length on both sides of the top surface of transfer modules (5), and bottom surface of storage slots (3) and elevator (4) over which the objects are moved for storing or retrieval with less friction, integral side, structures on two sides of transfer module (5) with their clamping arrangements to provide additional security while in transit; a system controller to co-ordinate, control and monitor the entire operations.

Transdermal patch for administering fentanyl

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

Transdermal patch for administering fentanyl

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

A composite material with enhanced mechanical properties and a method to fabricate the same

According to the present disclosure, a hydrophobic polymeric composite comprising a hydrophobic polymer matrix with hydrophobically modified particles dispersed therein is provided. The hydrophobically modified particles may be derived from hydrophilic particles modified with organic moieties. The hydrophobically modified particles may also take in the form of core-shell fibers with hydrophilic particles encapsulated inside the core of said fibers or in the form of monolithic fibers embedded with hydrophilic particles. The method for making hydrophobic polymeric composite comprising each of the various hydrophobically modified particles is also provided. The hydrophobic polymer matrix can be chosen from poly(alpha-hydroxyesters), polycarbonates, polyurethanes or polyalkanoates. For example, hydrophilic particles, such as barium sulphate, zirconium oxide, tantalum oxide or bismuth oxide, are dispersed in the hydrophobic biodegradable polymers, such as poly-(L-lactide) (PLLA).

Thermosensitive hydrogel compositions and ocular applications thereof

The present application provides a pharmaceutical composition for sustained ocular delivery of an agent, comprising (a) a thermosensitive hydrogel, preferably poloxamer; and (b) particles, preferably liposomes comprising the agent, stably dispersed in the thermosensitive hydrogel. Also provided herein are a method for sustained delivery of an agent to an eye in a subject and a method for treating or preventing an ocular disease, disorder or condition, said method comprising topically administering to the ocular surface or subconjunctivally injecting said pharmaceutical composition. In various embodiments, the pharmaceutical composition is a poloxamer 407 hydrogel comprising Senicapoc or 5-(4- phenoxybutoxy)psoralen (PAP-1 ) loaded dipalmitoylphosphatidylcholine (DPPC) liposomes dispersed therein.

Biodegradable thermoplastic elastomers

Transdermal patch for administering fentanyl

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

Optical cylinder and method of surface treatment of the same

Multi level automated car parking system

A structure having floors for receiving and delivery of cars, and parking floors. Receiving and delivery floors have slat conveyors with platform carriers placed in slots in the conveyor. Cars are parked by patrons on the platform carriers. After the patron exits the car the conveyor conveys the carrier on which the car is parked to the front of an elevator. A power arm in the elevator draws the carrier into the elevator, and the elevator rises to a parking floor. On the parking floor the elevator power arm pushes the platform carrier with the car on top onto a waiting transfer module, which moves laterally to the front of an allotted parking slot. A power arm on the transfer module pushes the platform carrier with the car on top into the parking slot. Upon the patron's return the car is retrieved as described above but in reverse order.

Polymeric stent and method of manufacture

A liposomal formulation for ocular drug delivery

The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2 μπι. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

Transdermal administration of fentanyl and analogs thereof

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

Thin polymer film drug reservoirs

The present invention relates to hydratable drug reservoir films for electrotransport drug delivery devices (10) and to electrotransport drug delivery systems containing the hydratable drug reservoirs (24, 30) and to methods for manufacturing and using such systems. The hydratable reservoir films according to this invention are easily manufacturable and rapidly imbibe water and/or drug solution with good water retention and stability.

Embolic device, an apparatus for embolizing a target vascular site and a method thereof

According to embodiments of the present invention, an embolic device for embolizing a target vascular site is provided. The embolic device includes a biodegradable shape memory element having an original shape and a deformed shape, wherein the biodegradable shape memory element in the deformed shape is in at least one dimension of a smaller size than the biodegradable shape memory element in the original shape, and wherein the biodegradable shape memory element is provided in the deformed shape and configured to resume the original shape in response to an external stimulus being applied to the biodegradable shape memory element in its deformed shape, to embolize the target vascular site and prevent fluid flow through the target vascular site. According to further embodiments of the present invention, an apparatus for embolizing a target vascular site and a method thereof are also provided.

TRANSDERMALE APPARATUS FOR DRUG ADMINISTRATION WITH A POLYURETHANE-ACTIVE RESERVOIR

Thin polymer film drug reservoirs

The present invention relates to hydratable drug reservoir films for electrotransport drug delivery devices (10) and to electrotransport drug delivery systems containing the hydratable drug reservoirs (24, 30) and to methods for manufacturing and using such systems. The hydratable reservoir films according to this invention are easily manufacturable and rapidly imbibe water and/or drug solution with good water retention and stability.

Optical cylinder and method of surface treatment of the same

Disclosed is an optical cylinder of a corneal prosthesis comprising: a) an optical cylinder comprising a solid polymer (preferably, PMMA), and b) a plurality of nanoparticles (preferably, hydroxyapatite, HAp) forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder. Also disclosed are methods of surface treatment of optical cylinders of corneal prostheses, and corneal prostheses thereof, comprising contacting an optical cylinder with a mixture comprising an organic solvent, a dispersant (i.e. PMMA), and a plurality of nanoparticles via dip- coating.

Stable liposomal formulations for ocular drug delivery

A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F 2a encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension

Various embodiments relate to the field of liposomal formulations for drug delivery, in particular, liposomal formulations for ocular drug delivery. More specifically, various embodiments relate to sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension.

Targeted drug delivery to the bone

A biodegradable ocular implant

The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

5-HYDROXYTHRIPTOPHAN (5-HTP) FORMULATIONS FOR BETTER AVAILABILITY FOR VARIOUS INDICATIONS

formulações de 5-hidroxitriptofano (5-htp) para melhor biodisponibilidade para várias indicações. são divulgadas aqui várias formas de dosagem de liberação prolongada gastrorretentiva que podem ser particularmente utilizáveis na entrega de 5-htp e outros agentes que poderiam se beneficiar de uma entrega no trato gastrointestinal superior.

A drug eluting member, a method of attaching the same and a method of fabricating the same, a device for holding the same and a drug eluting device

The present invention provides the following: a drug eluting member adapted to be attachable onto a perimeter edge of a lens portion of an intraocular lens, the drug eluting member includes an interfacing portion adapted to receive a portion of the perimeter edge; a drug eluting device that includes a first drug eluting member and a second drug eluting member, the first drug eluting member is adapted to be attached to the portion of the perimeter edge, and the second drug eluting member is adapted to be attached to another portion of the perimeter edge; a method of attaching a drug eluting member to a perimeter edge of the lens portion using the device, the method includes positioning the device with the drug eluting member held therein against a portion of the perimeter edge; and releasing the drug eluting member from the device to attach the drug eluting member to the lens portion; a method of fabricating the drug eluting member which includes providing a mold for molding the drug eluting member; discharging a forming solution from a nozzle onto the mold; and forming the drug eluting member.

Liposomal formulations

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WIP0 I PCT 0111111010 0111 °nolo III m nom INN Hi° oimIE (10) International Publication Number WO 2018/052373 Al (51) International Patent Classification: A61K 9/127 (2006.01) A61P 11/00 (2006.01) A61P 9/00 (2006.01) A61P 1/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/SG2017/050461 (22) International Filing Date: 14 September 2017 (14.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201607641Q 14 September 2016 (14.09.2016) SG (71) Applicants: NANYANG TECHNOLOGICAL UNIVERSITY [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG). SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singapore 168753 (SG). (72) Inventors: VENKATRAMAN, Subramanian; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). HUANG, Yingying; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). NAGLE, Amrita; c/o Nanyang Technolog- ical University, 50 Nanyang Avenue, Singapore 639798 (SG). NATARAJAN, Jayaganesh V; c/o Nanyang Tech- nological University, 50 Nanyang Avenue, Singapore 639798 (SG). FOIN, Nicolas Daniel Marie; c/o Singapore Health Services Pte Ltd, 31 Third Hospital Avenue, #03-03 Bowyer Block C, Singapore 168753 (SG). CHONG, Tze Tec; c/o Singapore Health Services Pte Ltd, 31 Third Hos- pital Avenue, #03-03 Bowyer Block C, Singapore 168753 (SG). PHUA, Jie Liang; c/o Nanyang Technological Uni- versity, 50 Nanyang Avenue, Singapore 639798 (SG). (74) Agent: VIERING, JENTSCHURA & PARTNER LLP; P.O Box 1088, Rochor Post Office, Rochor Road, Singapore 911833 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, ...

Change-based snapshot mechanism

Generation of new snapshots of a storage object are prompted based on changes to the storage object. An absolute storage change condition is satisfied when the aggregate amount of changed data since the most recent snapshot satisfies a threshold that represents a predefined amount of storage capacity, e.g., N GB. A percentage of used storage change condition is satisfied when the aggregate size of the changes expressed as a percentage of the provisioned storage capacity of snapped storage object satisfies a predetermined threshold, e.g., X % of Y TB. A percentage of provisioned storage change condition is satisfied when the aggregate amount of the changes in terms of percentage of utilized storage capacity of storage object satisfies a predetermined threshold expressed as a percentage of the utilized capacity of the storage object, e.g., P % of Z TB.

Transdermales pflaster zur verabreichung von fentanyl

Photodynamically active organosilica nanoparticles and medical uses thereof

The present application provides an organosilica nanoparticle comprising: (a) a photosensitizer for photodynamic therapy covalently incorporated therein; and (b) optionally, at least one agent encapsulated therein, as well as a pharmaceutical composition comprising said organosilica nanoparticle. Also provided herein are said organosilica nanoparticle or pharmaceutical composition for use as a medicament or in the treatment of a disease, disorder, or condition. More specifically, provided is a method for treating a disease, disorder, or condition in a subject using said aid organosilica nanoparticle or pharmaceutical composition.

Layer-by-layer coated nanoliposome for oral delivery of insulin

A multilayered liposome disclosed herein includes a liposome core defined by a lipid layer, and five or more coating layers surrounding the lipid layer, wherein the five or more coating layers include more than one positively charged polymeric layer and more than one negatively charged drug layer, wherein the more than one positively polymeric layer and the more than one negatively charged drug layer are deposited in an alternating manner, wherein one of the more than one positively charged polymeric layer is formed as an outmost coating layer, and wherein each of the more than one negatively charged drug layer includes insulin, an insulin-like factor, a growth factor, or a hormonal peptide. In one embodiment, an anion liposome core (HSPC/DPPG) is coated via a layer-by-layer approach with multilayers of oppositely charged insulin and chitosan layers.

Transdermale vorrichtung zur arzneistoffverabreichung mit einem polyurethanwirkstoffreservoir

Διαδερμικο επιθεμα για τη χορηγηση φεντανιλ

Περιγράφονται μέθοδος και μη ελεγχόμενο από την ταχύτητα μονολιθικό, υποκορεσμένο επίθεμα για την διαδερμική χορήγηση φεντανίλ και αναλόγων του, για αναλγητικούς σκοπούς, σε υποκείμενο, μέσω του δέρματος, για εκτεταμένη χρονική περίοδο.

Dünner polymerfilm als medikamentenreservoir

Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications

Disclosed herein are a range of gastroretentive sustained release dosage forms that may be particularly useful in the delivery of 5-HTP and other agents that would benefit from delivery to the upper gastrointestinal tract.

A device and method for forming an anastomotic joint between two parts of a body

Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Liposomal formulations

According to the present disclosure, a liposomal formulation comprising at least one uncharged phospholipid without cholesterol and at least one pharmaceutical agent, wherein the at least one uncharged phospholipid forms one or more lipid bilayers without cholesterol encapsulating the at least one pharmaceutical agent, is provided. The use(s) of such a liposomal formulation and method of producing such a liposomal formulation are also provided.

Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren

Occlusion device for closing anatomical defects

Occlusion device for closing anatomical defects

An occlusion device for closing an anatomical defect in tissue comprising a conduit connecting an opening on a first tissue and an opening on a second tissue is provided. The occlusion device comprises a scaffold comprising a) a proximal support structure comprising at least two arms; b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the device in the tissue; and c) a waist portion adapted for extending through the opening on the first tissue and connecting the proximal support structure with the distal support structure, wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise or consist of polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof. A method of closing an anatomical defect using the occlusion device is also provided.

Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren

A device and method for forming an anastomotic joint between two parts of a body

A device and method for forming an anastomotic joint between two parts of a human or animal body having a hollow connector with at least two proximal arms biased towards an open position; and at least two distal arms biased towards an open position, wherein in use when pressure is applied to the proximal arms to overcome the bias into a position in which the proximal arms are closer to each other; similarly pressure is applied to the distal arms to overcome the bias into a position in which the distal arms are closer to each other; the distal end can be pushed into a passage in the first human or animal body part until the distal arms are located in the first lumen of the first body part and released allowing the distal arms to move to the biased position to urge against the first lumen of the first body part; and the proximal end can be pushed into a passage in the second human or animal body part until the proximal arms are located in the second lumen of the second body part and released allowing the proximal arms to move to the biased position to urge against the second lumen of the second body part.

Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Pharmaceutical hydrogel formulations, drug delivery devices and methods

Pharmaceutical hydrogel formulations containing polyvinyl alcohol are provided. The formulations may serve as drug reservoirs in electrotransport drug delivery systems (10) or passive transdermal systems, or they may be used in a variety of other types of dosage forms, e.g., capsules, suppositories, aerosols, and the like. With these formulations, there is virtually no syneresis encountered upon long term storage, an advantage that derives from selecting the quantity of polyvinyl alcohol in the gel to correspond to the polymer's degree of hydrolysis.

Pharmaceutical hydrogel formulations, drug delivery devices and methods

Method and apparatus for supporting control windows

A method comprising: receiving, at a management application, a first definition of a control window, the first definition specifying the control window in a local time of a time zone where the management application is being executed, wherein the first definition identifies: (i) a first start time for the control window, (ii) a first end time for the control window, and (iii) one or more days of the week when the control window should be enforced; detecting an applicable time in the time zone, the applicable time being one of standard time or daylight savings time; generating a second definition of the control window that corresponds to the applicable time, the second definition specifying the control window in a standardized time format, the second definition being generated based on the first definition; and causing the control window to be enforced in a storage array in accordance with the second definition.

Layer-by-layer coated nanolipsome for oral delivery of insulin

A multilayered liposome disclosed herein includes a liposome core defined by a lipid layer, and five or more coating layers surrounding the lipid layer, wherein the five or more coating layers include more than one positively charged polymeric layer and more than one negatively charged drug layer, wherein the more than one positively polymeric layer and the more than one negatively charged drug layer are deposited in an alternating manner, wherein one of the more than one positively charged polymeric layer is formed as an outmost coating layer, and wherein each of the more than one negatively charged drug layer includes insulin, an insulin-like factor, a growth factor, or a hormonal peptide. In one embodiment, an anion liposome core (HSPC/DPPG) is coated via a layer-by-layer approach with multilayers of oppositely charged insulin and chitosan layers.

Layer-by-layer coated nanolipsome for oral delivery of insulin

A multilayered liposome disclosed herein includes a liposome core defined by a lipid layer, and five or more coating layers surrounding the lipid layer, wherein the five or more coating layers include more than one positively charged polymeric layer and more than one negatively charged drug layer, wherein the more than one positively polymeric layer and the more than one negatively charged drug layer are deposited in an alternating manner, wherein one of the more than one positively charged polymeric layer is formed as an outmost coating layer, and wherein each of the more than one negatively charged drug layer includes insulin, an insulin-like factor, a growth factor, or a hormonal peptide. In one embodiment, an anion liposome core (HSPC/DPPG) is coated via a layer-by-layer approach with multilayers of oppositely charged insulin and chitosan layers.

Formulations of 5-hydroxy tryptophan (5-HTP) for better bioavailability for various indications

Disclosed herein are a range of gastroretentive sustained release dosage forms that may be particularly useful in the delivery of 5-HTP and other agents that would benefit from delivery to the upper gastrointestinal tract.

Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting

Reivindicación 1: Un compuesto de fórmula (1) o una sal aceptable desde el punto de vista farmacéutico o un tautómero del mismo, caracterizado porque: cada uno de Z, Y¹, Y², y Y³ se selecciona independientemente a partir del grupo que consiste de CR¹, N, y NR², siempre que 1 - 3 de Z, Y¹, Y², y Y³ es un seleccionado independientemente N o NR²; X¹ se selecciona del grupo que consiste de O, S, N, NR², y CR¹; X² se selecciona del grupo que consiste de O, S, N, NR⁴, y CR⁵; cada ⁻ ⁻ ⁻ ⁻ ⁻ es de forma independiente un enlace doble o un enlace simple, siempre que en anillo de cinco elementos que comprende X¹ y X² es heteroarilo; el anillo de seis elementos que comprende Z, Y¹, Y², y Y³ es heteroarilo; y el anillo que comprende P¹, P², P³, P⁴, y P⁵ es aromático; W se selecciona del grupo que consiste de: (i) C(=O); (ii) C(=S); (iii) S(O)₁₋₂; (iv) C(=NRᵈ) o C(=N-CN); (v) C(=NH); (vi) C(=C-NO₂); (vii) S(=O)(=N(Rᵈ)); y (viii) S(=O)(=NH); Q se selecciona del grupo que consiste de: NH, N(alquilo C₁₋₆), *-NH-(alquileno C₁₋₃)-, y *-N(alquilo C₁₋₆)-(alquileno C₁₋₃)-, en donde el alquilo C₁₋₆ es opcionalmente sustituido con 1 - 2 Rᵃ seleccionado independientemente, y el asterisco representa el punto de unión a W; P¹, P², P³, P⁴, y P⁵ se definen de conformidad con (AA) o (BB): (AA) cada uno de P¹, P², P³, P⁴, y P⁵ se selecciona independientemente a partir del grupo que consiste de: N, CH, CR⁷, y CRᶜ, siempre que: 1 - 2 de P¹, P², P³, P⁴, y P⁵ es un CR⁷ seleccionado independientemente; o (BB) P¹ está ausente, con ello promueve al anillo de 5 miembros, cada uno de P², P³, P⁴, y P⁵ se selecciona independientemente a partir del grupo que consiste de O, S, N, NH, NRᵈ, NR⁷, CH, CR⁷, y CRᶜ; siempre que 1 - 3 de P², P³, P⁴, y P⁵ es O, S, N, NH, NRᵈ, o NR⁷; y 1 - 2 de P², P³, P⁴, y P⁵ es un seleccionado independientemente NR⁷ o CR⁷; cada R⁷ se selecciona independientemente a partir del grupo que consiste de: -R⁸ y -L³-R⁹; -R⁸ se selecciona del grupo que consiste de: (a) cicloalquilo C₃₋₁₂ o ...

Targetted drug delivery to the bone

The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.

Layer-by-layer coated nanolipsome for oral delivery of insulin

Nanoparticle-based nucleic acid delivery system

The invention provides a nanoparticle comprising a core portion formed from a charged material; and a shell portion comprising alternating layers of a positively charged polymer and a negatively charged nucleic acid, wherein: the shell portion comprises at least one layer of positively charged polymer and at least one layer of a negatively charged nucleic acid; the at least one layer of a negatively charged nucleic acid comprises at least one layer of a negatively charged mRNA; and the core portion has a charge that is opposite to a charge of an innermost layer of the shell portion. The invention also relates to pharmaceutical formulations comprising the nanoparticle of the invention, use of the nanoparticle or pharmaceutical formulations as a medicament, and methods of preparing the nanoparticle of the invention.

Non-biodegradable stent comprising a biodegradable coating and method of coating the same

The present invention relates to the field of non-biodegradable stents, and therein to non-biodegradable stents coated with at least one layer of a biodegradable polymer which maintains mechanical integrity of the coating both in storage and upon balloon expansion and which can optionally release drugs. The at least one polymer layer comprises a biodegradable polymer and a plasticizer. The present invention also relates to a manufacturing method of such a non-biodegradable stent.

Hyaluronic acid-based drug delivery systems

The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions.

Stable liposomal formulations for ocular drug delivery

A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F 2α encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Biodegradable ocular implant

Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.